Vnitr Lek 2011, 57(5):451-455

Treatment of critical limb ischemia and diabetic foot disease by the use of autologous stem cells

M. Dubský1,*, A. Jirkovská1, R. Bém1, L. Pagáčová2, V. Fejfarová1, M. Varga3, J. Skibová5, Š. Langkramer4, E. Syková4
1 Centrum diabetologie IKEM Praha, přednostka prof. MUDr. Terezie Pelikánová, DrSc.
2 Pracoviště laboratorních metod IKEM Praha, přednosta prof. MUDr. Antonín Jabor, CSc.
3 Klinika transplantační chirurgie IKEM Praha, přednosta prof. MUDr. Miloš Adamec, CSc.
4 Ústav experimentální medicíny AV ČR, v.v.i., ředitelka prof. MUDr. Eva Syková, DrSc.
5 Oddělení statistiky IKEM Praha

Aim:
The aim of our study was to assess safety and efectiveness of therapy of critical limb ischaemia by autologous stem cells and evaluation of potential adverse events.

Methods:
Fourteen patients were included into the study (11 men, 3 women, mean age 61.9 ± 9.6 years, mean diabetes duration 23.5 ± 11.1 years, mean glycated hemoglobin 6 ± 1 %). Eight patients were treated by bone marrow stromal cells, 6 patients by peripheral blood progenitor cells after stimulation by filgrastim. The suspension of stem cells was then applied into the muscles of ischemic limbs. We evaluated transcutaneous oxygen tension (TcPO2), subjective pain sensation assessed by Visual Analog Scale (VAS) and wound healing.

Results:
TcPO2 significantly increased in all patients from 10 ± 8.7 mm Hg before the treatment to 39.4 ± 9.5 mm Hg after 6 months (p = 0.0005) after stem cell therapy. We also observed significant area defect reduction and pain decrease during the follow-up period. Median of area defect was reduced from 4.3 (0.7 - 31.7) before the treatment to 0.06 (0 - 0.5) cm2 after 6 months from the treatment (p = 0.0078). Decrease in rest pain was observed in all patients, mean VAS decreased from 5.3 ± 1.8 to 1.1 ± 1.3 after 6 months (p = 0.002).

Conclusion:
Our study suggests that stem cell therapy of diabetic foot disease is an effective therapeutic option with no adverse events for patients with severe peripehral arterial disease. This treatment leads to increase of transcutanous oxygen tension, improves wound healing and decreases the rest pain.

Keywords: stem cells; diabetic foot; peripheral arterial disease; revascularization

Received: October 6, 2010; Accepted: December 3, 2010; Published: May 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dubský M, Jirkovská A, Bém R, Pagáčová L, Fejfarová V, Varga M, et al.. Treatment of critical limb ischemia and diabetic foot disease by the use of autologous stem cells. Vnitr Lek. 2011;57(5):451-455.
Download citation

References

  1. Jirkovská A. Ischemická choroba dolních končetin u pacientů s diabetem: Konzervativní terapie. In: Jirkovská A (ed.). Syndrom diabetické nohy. Praha: Maxdorf 2006; 161-165.
  2. Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease: Meta-analysis and systematic review of the literature. Atherosclerosis 2010; 209: 10-17. Go to original source... Go to PubMed...
  3. Awad O, Dedkov EI, Jiao C et al. Differential healing activities of CD34+ and CD14+ endothelial cell progenitors. Arterioscler Thromb Vasc Biol 2006; 26: 758-764. Go to original source... Go to PubMed...
  4. Timmermans F, Van Hauwermeiren F, De Smedt M et al. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol 2007; 27: 1572-1579. Go to original source... Go to PubMed...
  5. Matoba S, Matsubara H. Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for peripheral artery diseases by autologous bone marrow cell transplantation. Curr Pharm Des 2009; 15: 2769-2777. Go to original source... Go to PubMed...
  6. Tateishi-Yuayama E, Matsubara H, Murohara T et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomized controlled trial. Lancet 2002; 360: 427-435. Go to original source... Go to PubMed...
  7. Huang P, Li S, Han M et al. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005; 28: 2155-2160. Go to original source... Go to PubMed...
  8. Al Mheid I, Quyyumi AA. Cell therapy in peripheral arterial disease. Angiology 2009; 59: 705-716. Go to original source... Go to PubMed...
  9. Attanasio S, Snell J. Therapeutic angiogenesis in the management of critical limb ischemia: current concepts and review. Cardiol Rev 2009; 17: 115-120. Go to original source... Go to PubMed...
  10. Wahlberg E. Angiogenesis and arteriogenesis in limb ischemia. J Vasc Surg 2003; 38: 198-203. Go to original source... Go to PubMed...
  11. Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab Res Rev 2004; 20: S90-S95. Go to original source... Go to PubMed...
  12. Gough A, Clapperton M, Rolando N et al. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 1997; 350: 855-859. Go to original source... Go to PubMed...
  13. Procházka V, Gumulec J, Chmelová J et al. Autologous bone marrow stem cell transplantation in patients with end-stage chronical critical limb ischemia and diabetic foot. Vnitř Lék 2009; 55: 173-178.
  14. Dubský M, Jirkovská A, Bém R et al. Možnosti buněčné terapie v léčbě ischemické choroby dolních končetin u syndromu diabetické nohy. DMEV 2009; 12: 128-132.
  15. Lawall H, Bramlage P, Amann B. Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal. Thromb Haemost 2010; 103: 696-709. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.